» Articles » PMID: 35418743

Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014-2019)

Overview
Journal Clin Ophthalmol
Publisher Dove Medical Press
Specialty Ophthalmology
Date 2022 Apr 14
PMID 35418743
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess the incremental burden of corneal transplant surgery for US commercially insured patients with Fuchs endothelial corneal dystrophy (FECD) treated with endothelial keratoplasty (EK) compared to controls.

Methods: The study design was retrospective cohort using IBM MarketScan claims (January 2014-September 2019) and included EK-treated (N=1562) and control patients (N=23,485) having ≥12 months' enrollment before and after diagnosis, who were subsequently matched on select characteristics. The index date was the beginning of the pre-operative period (3 months before EK); synthetic EK index was assigned for controls. All-cause, eye-disease, and complication-related healthcare resource utilization (HCRU) and costs were compared up to 36 months post index. For a small subset of patients, patient data were linked to the Health and Productivity Management supplemental database, which integrates data on productivity loss and disability payments.

Results: Matched cohorts included 804 EK-treated and 1453 controls with average age 65.7 years, 1383 (61%) female. Over 12 months of follow-up, all-cause ($41,199 vs $20,222, p<0.001) and eye-disease related costs ($22,951 vs $1389, p<0.001) were higher among EK-treated patients than controls. The cost differential increased additionally by $1000-$2000 per annum by 36 months of follow-up. While balanced at baseline, over follow-up EK-treated patients had higher prevalence of glaucoma, elevated intraocular pressure, cataract, cataract surgery, diagnosis of cornea transplant rejection, retinal edema. By 36 month of follow-up, EK-treated patients had 9 more short-term disability days, resulting in $2992 additional burden of disability payments.

Conclusion: This study found a higher cost burden among FECD patients receiving EK treatment versus those who did not. With a shift in management of FECD, cost burden estimates generated in this study could serve as an important benchmark for future studies.

Citing Articles

Endoplasmic Reticulum-Mitochondria Crosstalk in Fuchs Endothelial Corneal Dystrophy: Current Status and Future Prospects.

Kasi A, Steidl W, Kumar V Int J Mol Sci. 2025; 26(3).

PMID: 39940664 PMC: 11817211. DOI: 10.3390/ijms26030894.


Descemet Stripping Only: Long-Term Outcomes.

Hakim F, Nagra A, Dhaliwal D Cornea. 2023; 43(8):994-998.

PMID: 37921677 PMC: 11058104. DOI: 10.1097/ICO.0000000000003421.

References
1.
Gibbons A, Leung E, Yoo S . Cost-Effectiveness Analysis of Descemet's Membrane Endothelial Keratoplasty Versus Descemet's Stripping Endothelial Keratoplasty in the United States. Ophthalmology. 2018; 126(2):207-213. PMC: 6606558. DOI: 10.1016/j.ophtha.2018.09.033. View

2.
Zafar S, Wang P, Woreta F, Aziz K, Makary M, Srikumaran D . Risk Factors for Repeat Keratoplasty after Endothelial Keratoplasty in the Medicare Population. Am J Ophthalmol. 2020; 221:287-298. DOI: 10.1016/j.ajo.2020.08.006. View

3.
Matthaei M, Hribek A, Clahsen T, Bachmann B, Cursiefen C, Jun A . Fuchs Endothelial Corneal Dystrophy: Clinical, Genetic, Pathophysiologic, and Therapeutic Aspects. Annu Rev Vis Sci. 2019; 5:151-175. DOI: 10.1146/annurev-vision-091718-014852. View

4.
Soh Y, Kocaba V, Pinto M, Mehta J . Fuchs endothelial corneal dystrophy and corneal endothelial diseases: East meets West. Eye (Lond). 2019; 34(3):427-441. PMC: 7042366. DOI: 10.1038/s41433-019-0497-9. View

5.
Gain P, Jullienne R, He Z, Aldossary M, Acquart S, Cognasse F . Global Survey of Corneal Transplantation and Eye Banking. JAMA Ophthalmol. 2015; 134(2):167-73. DOI: 10.1001/jamaophthalmol.2015.4776. View